Defying the economists: A decrease in heart rate improves not only cardiac but also endothelial function

Research output: Contribution to journalComment/debate

12 Citations (Scopus)

Abstract

Ivabradine has proven therapeutic efficacy for cardiac ischaemia and, until proved otherwise, is a very specific inhibitor of the cardiac sinoatrial node I f current. In the current issue of the British Journal of Pharmacology, Drouin et al. demonstrated that chronic treatment of the human apoB-100 transgene dyslipidaemic mouse with ivabradine significantly improved endothelium-dependent vasodilatation to ACh in renal and cerebral arteries and that the beneficial effects of ivabradine result secondarily to the lowering of heart rate. These data suggest that drugs that target the I f current have potential benefits not only as anti-ischaemics but also as agents for the treatment of endothelial dysfunction.

Original languageEnglish
Pages (from-to)727-728
Number of pages2
JournalBritish Journal of Pharmacology
Volume154
Issue number4
DOIs
Publication statusPublished - 21 Jun 2008

Fingerprint

ivabradine
Heart Rate
Apolipoprotein B-100
Sinoatrial Node
Cerebral Arteries
Renal Artery
Transgenes
Vasodilation
Endothelium
Ischemia
Pharmacology
Pharmaceutical Preparations

Keywords

  • Cerebral artery
  • Dyslipidaemia
  • Endothelial dysfunction
  • If channel
  • Ivabradine
  • Renal artery

ASJC Scopus subject areas

  • Pharmacology

Cite this

Defying the economists : A decrease in heart rate improves not only cardiac but also endothelial function. / Triggle, Christopher.

In: British Journal of Pharmacology, Vol. 154, No. 4, 21.06.2008, p. 727-728.

Research output: Contribution to journalComment/debate

@article{59c4c2456ab34d76bb15f03a08df9dc8,
title = "Defying the economists: A decrease in heart rate improves not only cardiac but also endothelial function",
abstract = "Ivabradine has proven therapeutic efficacy for cardiac ischaemia and, until proved otherwise, is a very specific inhibitor of the cardiac sinoatrial node I f current. In the current issue of the British Journal of Pharmacology, Drouin et al. demonstrated that chronic treatment of the human apoB-100 transgene dyslipidaemic mouse with ivabradine significantly improved endothelium-dependent vasodilatation to ACh in renal and cerebral arteries and that the beneficial effects of ivabradine result secondarily to the lowering of heart rate. These data suggest that drugs that target the I f current have potential benefits not only as anti-ischaemics but also as agents for the treatment of endothelial dysfunction.",
keywords = "Cerebral artery, Dyslipidaemia, Endothelial dysfunction, If channel, Ivabradine, Renal artery",
author = "Christopher Triggle",
year = "2008",
month = "6",
day = "21",
doi = "10.1038/bjp.2008.168",
language = "English",
volume = "154",
pages = "727--728",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Defying the economists

T2 - A decrease in heart rate improves not only cardiac but also endothelial function

AU - Triggle, Christopher

PY - 2008/6/21

Y1 - 2008/6/21

N2 - Ivabradine has proven therapeutic efficacy for cardiac ischaemia and, until proved otherwise, is a very specific inhibitor of the cardiac sinoatrial node I f current. In the current issue of the British Journal of Pharmacology, Drouin et al. demonstrated that chronic treatment of the human apoB-100 transgene dyslipidaemic mouse with ivabradine significantly improved endothelium-dependent vasodilatation to ACh in renal and cerebral arteries and that the beneficial effects of ivabradine result secondarily to the lowering of heart rate. These data suggest that drugs that target the I f current have potential benefits not only as anti-ischaemics but also as agents for the treatment of endothelial dysfunction.

AB - Ivabradine has proven therapeutic efficacy for cardiac ischaemia and, until proved otherwise, is a very specific inhibitor of the cardiac sinoatrial node I f current. In the current issue of the British Journal of Pharmacology, Drouin et al. demonstrated that chronic treatment of the human apoB-100 transgene dyslipidaemic mouse with ivabradine significantly improved endothelium-dependent vasodilatation to ACh in renal and cerebral arteries and that the beneficial effects of ivabradine result secondarily to the lowering of heart rate. These data suggest that drugs that target the I f current have potential benefits not only as anti-ischaemics but also as agents for the treatment of endothelial dysfunction.

KW - Cerebral artery

KW - Dyslipidaemia

KW - Endothelial dysfunction

KW - If channel

KW - Ivabradine

KW - Renal artery

UR - http://www.scopus.com/inward/record.url?scp=45249108656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45249108656&partnerID=8YFLogxK

U2 - 10.1038/bjp.2008.168

DO - 10.1038/bjp.2008.168

M3 - Comment/debate

C2 - 18438420

AN - SCOPUS:45249108656

VL - 154

SP - 727

EP - 728

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 4

ER -